Abstract:Objective To compare the efficacy and safety of etanercept injection 50 mg once weekly combined with methotrexate (MTX) therapy for patients with active rheumatoid arthritis.Methods This study consists of 2 parts：a 12-week double-blind treatment period (part A) followed by a 12-week open-label safety study period (part B).The randomization of treatments in double-blind treatment period was completed through the clinical operations randomization environment (CORE) system.During part A,the subjects were randomly assigned to the etanercept 50 mg or placebo group. The dosage regimen for etanercept was 50 mg administered subcutaneously once weekly while MTX was administered orally.All subjects who completed part A received 50 mg etanercept once weekly and MTX1 during the open-label treatment.The primary endpoint was ACR 20 response at week 12.Secondary endpoint variables included physician／patient global assessments of disease activities,duration of morning stiffness,pain visual analog scale (VAS),health assessment questi onnaire (HAQ),CRP level and tender and swollen joint counts .The results of safety between the two groups were compared.The primary endpoint and other secondary binary endpoints were analyzed using the Fisher’s exact test.For continuous endpoints.the change from baseline was analyzed with analysis of covariance. Results One hundred and fifty six subjects satisfied modified intent-to-treat (mITT) population were enrolled during part A,of which 77 subjects were in the etanercept+MTX group,and 79 subjects were in the placebo+MTX group respectively.A total of 149 subjects completed part A.As early as week 4.the ACR 20 response achieved 39％ (30,77) in the etanercept group,which was significantly higher than that of the placebo group [16％(13／79),P<0.001].At week 12,the ACR 20 respouse achieved 62％(48,77)in the etanercept group and 23％(18／79) in the placebo group (P<0.01).From week 4,other study endpoints including physician global assessment,patient global assessment,duration of morning stiffness,pain VAS,HAQ,CRP level,tender joint counts,swollen joint counts were also compared.The results showed that all above efficacy endpoints in the etanercept+MTX group were better than those of the placebo+MTX group(P<0.01).But there Was no significant difference in the total adverse eriects between the two groups.Conclusion Etanercept 50 mg once weekly + MTX treatment for 24 weeks is well tolerated.During the first 12-week treatment period,the etanercept group has shown a rapid efficacy onset and a significantly better therapeutic effect compared to that of the placebo group.

Efficacy of Leflunomide Plus Methotrexate for Psoriatic Arthritis

The efficacy and safety of iguratimod or leflunomide combined with methotrexate in treating active rheumatoid arthritis (TRANMOD): a multicenter, randomized, double-blinded, double dummy and controlled clinical trial

Efficacy of Leflunomide Compared to Methotrexate in the Treatment of Moderate to Severe Plaques Psoriasis: A Randomized Controlled Clinical Trial

Safety and Efficacy of Etanercept-Methotrexate Combination Therapy in Patients with Rhupus: an Observational Study of Non-glucocorticoid Treatment for Rheumatic Diseases

Effectiveness and Safety of Methotrexate Versus Leflunomide in 12-Month Treatment for Takayasu Arteritis.

Efficacy and Safety of Weekly Leflunomide for the Treatment of Early Rheumatoid Arthritis: a Randomized, Multi‐center Study

Leflunomide, a New Disease-Modifying Drug for Treating Active Rheumatoid Arthritis in Methotrexate-Controlled Phase II Clinical Trial.

Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World

Clinical Analysis of Chinese Patients With Rheumatoid Arthritis Treated With Leflunomide and Methotrexate Combined With Different Dosages of Glucocorticoid

Clinical study on long-term effectiveness of leflunomide compared with sulfasalazine in treatment of ankylosing spondylitis

Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial

Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

Effect of Teriflunomide Combined with Methotrexate on Fibroblast-like Synoviocytes in Rheumatoid Arthritis

Outcomes of combined use of leflunomide and low-dose prednisone in the treatment of elder patients with rheumatoid arthritis

Leflunomide Increases Hepatic Exposure to Methotrexate and Its Metabolite by Differentially Regulating Multidrug Resistance–Associated Protein Mrp2/3/4 Transporters via Peroxisome Proliferator–Activated Receptor α Activation

Efficacy of low-dose leflunomide in lupus nephritis: A multi-center prospective study

Treatment of Proliferative Lupus Nephritis with Leflunomide and Steroid: a Prospective Multi-Center Controlled Clinical Trial

A multi-center,double-blind,randomized,placebo-controlled study on the efficacy and safety of etanercept and methotrexate in the treatment of active rheumatoid arthritis

Safety and Efficacy of Methotrexate for Chinese Adults with Psoriasis with and Without Psoriatic Arthritis

Study on the Mechanism of the Combination of Methotrexate and Leflunomide in the Treatment of Rheumatoid Arthritis Based on Network Pharmacology, Molecular Docking, and in vitro Experimental Verification